HUMA
Humacyte, Inc.
$1.05
-2.31%
$234.2M
No data for this timeframe.
Vol
Market Cap$234.2M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders50 funds
Inst. Value$21.0M
Inst. Activity14 buys / 1 sells
Insider Activity2B / 2S
Insider Net $-$22.5K
Reddit Sentiment57° Neutral
SEC Reports5
Press Releases6
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001818382·Prev Close $1.08
Recent Activity
Jun 12, 2026
SEC
A strong institutional cluster formed in HUMA during 2024-Q3, with 15 buyers accumulating $10.9M in holdings (net +$6.4M
INST-CLUSTER — Impact 5/10
Jun 11, 2026
SEC
Humacyte priced a $50M underwritten public offering of 47.6M shares at $1.05/share, with an underwriter option for an ad
8-K — Impact 6/10
Jun 11, 2026
Press
Humacyte priced a $50M underwritten public offering of 47.6M shares at $1.05 per share, representing a roughly 20% disco
Impact 6/10
Jun 11, 2026
offering
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
<p>DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-sta
Jun 11, 2026
Press
Humacyte, Inc. has commenced an underwritten public offering of its common stock. The size and pricing of the offering h
Impact 5/10
Jun 11, 2026
Insider
Bamforth John Philip was granted 80,000 shares
Director
Jun 11, 2026
Insider
Dougan Brady W was granted 0 shares
Director
Jun 11, 2026
Insider
Brown Emery N. was granted 80,000 shares
Director
Price Targets
$2.10
+99.1% upside
Strong Buy
Current $1.06
Low $1.00
Median $2.00
High $4.00
5 analysts
$1.00
$4.00
Analyst Ratings
3Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jun 8, 2026 | BTIG | REITERATE | Buy → Buy |
| Jun 1, 2026 | Benchmark | MAINTAIN | Speculative Buy → Speculative Buy |
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 14, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.10 ▲ +8.2% | $-0.12 — $-0.09 | 57% YoY | 3 |
| Next Q | $-0.09 ▲ +19.4% | $-0.10 — $-0.07 | 21% YoY | 3 |
| Current FY | $-0.36 ▲ +16.5% | $-0.37 — $-0.36 | -40% YoY | 3 |
| Next FY | $-0.26 ▼ -41.8% | $-0.28 — $-0.24 | 28% YoY | 3 |
Latest Reports
BULLISH
INST-CLUSTER
5/10
A strong institutional cluster formed in HUMA during 2024-Q3, with 15 buyers accumulating $10.9M in holdings (net +$6.4M
Jun 12, 2026
BEARISH
8-K
6/10
Humacyte priced a $50M underwritten public offering of 47.6M shares at $1.05/share, with an underwriter option for an ad
Jun 11, 2026
BEARISH
Press
6/10
Humacyte priced a $50M underwritten public offering of 47.6M shares at $1.05 per share, representing a roughly 20% disco
Jun 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $7.5M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.3M | — |
| STATE STREET CORP | $1.8M | TRIM |
| Woodline Partners LP | $1.2M | TRIM |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $860.6K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 11, 2026 | Bamforth John | A | $0.00 |
| Jun 11, 2026 | Dougan Brady | A | $0.00 |
| Jun 11, 2026 | Brown Emery | A | $0.00 |
| Jun 11, 2026 | Seimetz Diane | A | $0.00 |
| Jun 11, 2026 | Jones Keith | A | $0.00 |
Reddit Sentiment
57°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $21.0M total value (34,528,159 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 14 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 12,316,955 | $7.5M | 35.6% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 7,158,162 | $4.3M | 20.7% | — |
| 3 | STATE STREET CORP | 3,043,929 | $1.8M | 8.8% | TRIM -45.2% |
| 4 | Woodline Partners LP | 2,002,582 | $1.2M | 5.8% | TRIM -49.3% |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,417,825 | $860.6K | 4.1% | — |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,291,345 | $783.5K | 3.7% | — |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,058,048 | $641.9K | 3.1% | — |
| 8 | VANGUARD FIDUCIARY TRUST CO | 1,011,029 | $613.7K | 2.9% | — |
| 9 | GOLDMAN SACHS GROUP INC | 677,015 | $410.7K | 2.0% | — |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 414,000 | $252.5K | 1.2% | — |
| 11 | BANK OF AMERICA CORP /DE/ | 396,113 | $240.0K | 1.1% | — |
| 12 | Nuveen, LLC | 349,435 | $212.0K | 1.0% | ADD +33.6% |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 285,500 | $174.2K | 0.8% | — |
| 14 | NOMURA HOLDINGS INC | 240,000 | $145.6K | 0.7% | — |
| 15 | CITADEL ADVISORS LLC | 232,100 | $140.8K | 0.7% | ADD +42.9% |
| 16 | ALLIANCEBERNSTEIN L.P. | 145,560 | $139.8K | 0.7% | — |
| 17 | GROUP ONE TRADING LLC | 215,476 | $130.7K | 0.6% | ADD +89.7% |
| 18 | MORGAN STANLEY | 186,743 | $113.3K | 0.5% | NEAR_EXIT -92.5% |
| 19 | TWO SIGMA INVESTMENTS, LP | 177,536 | $107.7K | 0.5% | DOUBLED +162.2% |
| 20 | RHUMBLINE ADVISERS | 174,549 | $105.9K | 0.5% | ADD +51.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Nuveen, LLC | ADD | 261,489 | 349,435 | +33.6% | $212.0K | 2026-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 2,505,428 | 186,743 | -92.5% | $113.3K | 2026-Q1 |
| Invesco Ltd. | DOUBLED | 38,824 | 172,435 | +344.1% | $104.6K | 2026-Q1 |
| DEUTSCHE BANK AG\ | ADD | 108,752 | 168,628 | +55.1% | $102.9K | 2026-Q1 |
| CWM, LLC | DOUBLED | 1,237 | 97,873 | +7812.1% | $59.4K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | DOUBLED | 10,140 | 78,604 | +675.2% | $50.5K | 2026-Q1 |
| MetLife Investment Management, LLC | DOUBLED | 12,862 | 70,106 | +445.1% | $42.5K | 2026-Q1 |
| Merit Financial Group, LLC | DOUBLED | 18,015 | 41,958 | +132.9% | $25.5K | 2026-Q1 |
| FMR LLC | DOUBLED | 6,817 | 28,562 | +319.0% | $17.3K | 2026-Q1 |
| Independent Advisor Alliance | ADD | 14,500 | 26,500 | +82.8% | $16.1K | 2026-Q1 |
| HighTower Advisors, LLC | ADD | 18,303 | 23,085 | +26.1% | $14.0K | 2026-Q1 |
| Vanguard Personalized Indexing Management, LLC | ADD | 12,116 | 16,442 | +35.7% | $10.0K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 270 | 10,150 | +3659.3% | $6.2K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | ADD | 3,098 | 5,101 | +64.7% | $3.1K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 76,017 | 112,172 | +47.6% | $69.00 | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 818,954 | 488,369 | -40.4% | $468.8K | 2025-Q4 |
| GROUP ONE TRADING LLC | ADD | 139,473 | 264,597 | +89.7% | $254.1K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 98,021 | 174,470 | +78.0% | $167.6K | 2025-Q4 |
| Waverly Advisors, LLC | NEAR_EXIT | 267,041 | 19,051 | -92.9% | $18.3K | 2025-Q4 |
| Merit Financial Group, LLC | TRIM | 27,668 | 18,015 | -34.9% | $17.3K | 2025-Q4 |
| Legal & General Group Plc | ADD | 12,009 | 15,617 | +30.0% | $15.0K | 2025-Q4 |
| Independent Advisor Alliance | TRIM | 36,240 | 14,500 | -60.0% | $13.9K | 2025-Q4 |
| MetLife Investment Management, LLC | NEAR_EXIT | 57,830 | 12,862 | -77.8% | $12.4K | 2025-Q4 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | TRIM | 13,600 | 10,140 | -25.4% | $11.0K | 2025-Q4 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 6,123 | 9,100 | +48.6% | $8.7K | 2025-Q4 |
13 unique insiders with 15 transactions. Net insider value: -$22.5K ($59.8K bought, $82.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Bamforth John Philip | Director | AWARD | 80,000 | — | — |
| Jun 11, 2026 | Dougan Brady W | Director | AWARD | 0 | — | — |
| Jun 11, 2026 | Brown Emery N. | Director | AWARD | 80,000 | — | — |
| Jun 11, 2026 | Seimetz Diane | Director | AWARD | 80,000 | — | — |
| Jun 11, 2026 | Jones Keith Anthony | Director | AWARD | 80,000 | — | — |
| Jun 11, 2026 | Green Charles Bruce | Director | AWARD | 80,000 | — | — |
| Jun 11, 2026 | Constantino Michael T. | Director | AWARD | 80,000 | — | — |
| Jun 11, 2026 | Wallace Max N. | Director | AWARD | 80,000 | — | — |
| Jun 11, 2026 | Sebelius Kathleen | Director | AWARD | 80,000 | — | — |
| Jun 11, 2026 | Niklason Laura E | President, CEO and Director | AWARD | 80,000 | — | — |
| Jun 11, 2026 | Windham-Bannister Susan Richards | Director | AWARD | 80,000 | — | — |
| May 19, 2026 | Sebelius Kathleen | Director | BUY | 56,818 | $0.8800 | $50.0K |
| May 18, 2026 | Parikh Shamik J | Chief Medical Officer | SELL | 45,887 | $0.8967 | $41.1K |
| May 18, 2026 | Sander Dale A. | CFO and Chief Corp. Dev. Off | SELL | 45,887 | $0.8967 | $41.1K |
| May 18, 2026 | Constantino Michael T. | Director | BUY | 11,000 | $0.8945 | $9.8K |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 1 mixed, 2 neutral. Avg impact: 4.4/10.
BULLISH
INST-CLUSTER
5/10
A strong institutional cluster formed in HUMA during 2024-Q3, with 15 buyers accumulating $10.9M in
Jun 12, 2026
BEARISH
8-K
6/10
Humacyte priced a $50M underwritten public offering of 47.6M shares at $1.05/share, with an underwri
Jun 11, 2026
NEUTRAL
CLUSTER
3/10
Two C-suite insiders (CFO and Chief Medical Officer) sold ~$82K in open-market sales on 2026-05-18,
May 20, 2026
MIXED
PRESS-RELEASE
6/10
Humacyte reported Q1 2026 revenue of $0.5M (vs $1.5M consensus) and EPS of -$0.13 (vs -$0.12 consens
May 13, 2026
NEUTRAL
PRESS-RELEASE
2/10
Humacyte announced it will release Q1 2026 financial results on May 13, 2026, with no preliminary fi
May 8, 2026
BEARISH
6/10
Humacyte priced a $50M underwritten public offering of 47.6M shares at $1.05 per share, representing
Jun 11, 2026
BEARISH
5/10
Humacyte, Inc. has commenced an underwritten public offering of its common stock. The size and prici
Jun 11, 2026
BULLISH
7/10
Humacyte announced positive top-line interim results from the V012 Phase 3 study of its acellular ti
Jun 10, 2026
BULLISH
7/10
Humacyte's Marketing Authorization Application (MAA) for its acellular tissue engineered vessel (Sym
Apr 21, 2026
NEUTRAL
3/10
Humacyte announced it will release its Q4 and full-year 2025 financial results on March 27, 2026, fo
Mar 23, 2026
MIXED
5/10
Humacyte announced a $1.475 million binding purchase commitment for its Symvess product to support a
Mar 19, 2026
Current analyst consensus: Strong Buy (82% buy). Based on 11 analysts: 3 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$2.10 mean target
+99.1% upside
Strong Buy (1.60)
$1.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $1.06 |
| Target Low | $1.00 |
| Target Mean | $2.10 |
| Target Median | $2.00 |
| Target High | $4.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.10 | $-0.12 | $-0.09 | 57.0% | +8.2% | 1↑ 1↓ | $0.0B | 269.7% | 3 |
| Next Q 2026-09-30 |
$-0.09 | $-0.10 | $-0.07 | 21.2% | +19.4% | 2↑ 1↓ | $0.0B | 189.0% | 3 |
| Current FY 2026-12-31 |
$-0.36 | $-0.37 | $-0.36 | -39.7% | +16.5% | 2↑ 1↓ | $0.0B | 218.8% | 3 |
| Next FY 2027-12-31 |
$-0.26 | $-0.28 | $-0.24 | 28.4% | -41.8% | 1↑ 1↓ | $0.0B | 308.7% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.103 | |
| 7d ago | $-0.120 | +0.017 |
| 30d ago | $-0.113 | +0.009 |
| 60d ago | $-0.113 | +0.009 |
| 90d ago | $-0.110 | +0.007 |
7 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jun 8, 2026 | BTIG | REITERATE | Buy | Buy |
| Jun 1, 2026 | Benchmark | MAINTAIN | Speculative Buy | Speculative Buy |
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 14, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| May 13, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Apr 28, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 28, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 24, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 21, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 8, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 31, 2026 | Benchmark | DOWNGRADE | Buy | Speculative Buy |
| Mar 30, 2026 | Piper Sandler | MAINTAIN | Neutral | Neutral |
| Mar 30, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 19, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 19, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 10, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 9, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | Benchmark | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 22, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| May 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| Apr 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| Jan 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
57°
Neutral
Bearish
Neutral
Bullish
11 mentions
2 bullish
0 bearish
8 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 1, 2026 | 4 | 50° Neutral | 0 | 0 | 4 |
| May 1, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 26, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 26, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 11, 2026
offering
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
<p>DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing unive
Jun 11, 2026
offering
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
<p>DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing unive
Jun 11, 2026
short_volume
Short Volume: HUMA — 57.5% short (9.1M / 15.9M)
Short: 9,112,426 | Exempt: 649,529 | TRF Vol: 15,855,184 | Short Ratio: 57.5% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
activist
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
<p>DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing unive
Jun 10, 2026
fda
Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
<p align="center"><em>- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during th
Jun 10, 2026
short_volume
Short Volume: HUMA — 55.5% short (1.9M / 3.4M)
Short: 1,906,926 | Exempt: 20,966 | TRF Vol: 3,434,750 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: HUMA — 55.2% short (2.0M / 3.6M)
Short: 1,991,242 | Exempt: 4,721 | TRF Vol: 3,608,747 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: HUMA — 56.4% short (2.6M / 4.5M)
Short: 2,562,930 | Exempt: 15,501 | TRF Vol: 4,540,881 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: HUMA — 62.0% short (1.3M / 2.2M)
Short: 1,347,384 | Exempt: 3,336 | TRF Vol: 2,172,438 | Short Ratio: 62.0% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: HUMA — 75.3% short (1.8M / 2.3M)
Short: 1,755,117 | Exempt: 100 | TRF Vol: 2,330,747 | Short Ratio: 75.3% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: HUMA — 61.6% short (2.8M / 4.5M)
Short: 2,775,372 | Exempt: 353,996 | TRF Vol: 4,504,437 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: HUMA — 70.0% short (3.4M / 4.9M)
Short: 3,427,762 | Exempt: 86,738 | TRF Vol: 4,899,758 | Short Ratio: 70.0% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_interest
FTD: HUMA — 721,360 shares ($0.8M) failed to deliver
Settlement: 20260514, Price: $1.13, FTD Value: $815,136.8, HUMACYTE INC
May 13, 2026
earnings
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - </em></p>
May 13, 2026
earnings_calendar
HUMA Q1 2026 Earnings Scheduled — 2026-05-13